Festive food and health benefits: Newcastle University experts examine Christmas dinner staples

Re­vance Ther­a­peu­tics, the mak­er of Botox com­peti­tor Daxxi­fy, will be ac­quired for more than $900 mil­lion. Crown Lab­o­ra­to­ries will buy out … Sign up to

Re­vance Ther­a­peu­tics se­cured an FDA ap­proval on Mon­day for its Botox ri­val Daxxi­fy in cer­vi­cal dys­to­nia, mark­ing the drug’s first ther­a­peu­tic in­di­ca­tion. Daxxi­fy was ap­proved

Share this article The fast track designation is set to expedite the development and review of EDG-5506. Credit: Gorodenkoff / Shutterstock.com. The US Food and